Skip to content

Aspen’s half-year gross revenue surges by 47% to R19 billion

05/03/15: Aspen’s half-year gross revenue surges by 47% to R19 billion Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), the fifth largest generic company in the world, has announced stellar results for the six months ended 31 December 2014, which have primarily been driven by its offshore businesses. GROUP PERFORMANCE Gross revenue increased…

Read More

Acquisition of rights to an anti-coagulant product from Novartis

26/01/15: Aspen is pleased to announce that Aspen Global Incorporated (“AGI”), a wholly owned subsidiary of Aspen Holdings, has entered into an agreement with Novartis AG in terms of which it will acquire the rights to Mono-Embolex®, an injectable anti-coagulant, for a consideration of US$142.3 million. Mono-Embolex is a heparin based anti-coagulant sold in the…

Read More

2014 Anti-retroviral tender results

24/12/14: Following the announcement of the Anti-Retroviral (ARV) Tender results by the South African National Treasury Department, Aspen Pharmacare Holdings Limited is pleased to announce that its South African operating company (Pharmacare Limited t/a Aspen Pharmacare) has been successful in winning a number of key products in the tender Aspen’s award included 25% of the…

Read More

Stephen Saad’s Aspen: From JSE newcomer to R150bn valuation in 16 years

16/09/14: In 1998, Stephen Saad and Gus Attridge took their ambitions public through the reverse takeover by their year-old business into JSE-listed Medhold. A year later they pulled off a R2.4bn hostile takeover of the well resourced but poorly managed SA Druggists. And the rest is history. Now a multinational corporation, last week Aspen delivered another…

Read More

Aspen’s revenue soars by 53% to R29.5 billion

10/09/14: Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), the fifth largest generic company in the world and Africa’s largest pharmaceutical manufacturer, has announced excellent results for the year ended 30 June 2014. GROUP PERFORMANCE Revenue increased by 53% to R29.5 billion. Operating profit rose by 47% to R7.4 billion. Normalised headline earnings,…

Read More

Honorary Doctor of Commerce Degree conferred on Stephen Saad

10/04/14: [embedded content] Port Elizabeth – The Nelson Mandela Metropolitan University (NMMU) today conferred the degree of Doctor of Commerce (honoris causa) on Stephen Saad, Aspen Group Co-Founder and Chief Executive. Chancellor of the NMMU, Santie Botha said, ‘’It is an honour for NMMU to confer this honorary degree on Stephen Saad. His vision and…

Read More

Aspen’s half-year revenue increases to R12 billion

06/03/14: Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), the ninth largest generic company in the world and Africa’s largest pharmaceutical manufacturer, has announced excellent results for the six months ended 31 December 2013. Group Performance Revenue increased by 33% to R12.0 billion. Operating profit improved by 16% to R2.9 billion after absorbing…

Read More

Aspen’s growth formula

16/01/14: On a recent holiday to Disney World with his family, Aspen Pharmacare CE Stephen Saad wandered into a pharmacy while his children enjoyed the rides. On a shelf he found Murine Clear Eyes, the eye drops made at Aspen’s Port Elizabeth plant. “About 2m-3m packs a month are sold around the world but it…

Read More
Scroll To Top